Benefits of Steroid Therapy in COVID-19 Patients with Different PaO2/FiO2 Ratio at Admission

Introduction: The use of steroid therapy in patients within the context of SARS-CoV-2 infection is still a matter of debate. This study aimed to evaluate if potential steroid benefits could be predicted by the ratio of arterial oxygen partial pressure (PaO2 in mmHg) to fractional inspired oxygen (Fi...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical medicine 2021-07, Vol.10 (15), p.3236
Main Authors: Vita, Serena, Centanni, Daniele, Lanini, Simone, Piselli, Pierluca, Rosati, Silvia, Giancola, Maria, Mondi, Annalisa, Pinnetti, Carmela, Topino, Simone, Chinello, Pierangelo, Mosti, Silvia, Gualano, Gina, Faraglia, Francesca, Iacomi, Fabio, Marchioni, Luisa, Maritti, Micaela, Girardi, Enrico, Ippolito, Giuseppe, Nicastri, Emanuele
Format: Article
Language:English
Subjects:
Asymptomatic
Bias
Cardiovascular disease
Chronic obstructive pulmonary disease
Clinical medicine
Coronaviruses
COVID-19
Cytokines
Drug use
Hospitals
Inflammation
Mortality
Patients
Pneumonia
Sensitivity analysis
Severe acute respiratory syndrome coronavirus 2
Steroids
Variables
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction: The use of steroid therapy in patients within the context of SARS-CoV-2 infection is still a matter of debate. This study aimed to evaluate if potential steroid benefits could be predicted by the ratio of arterial oxygen partial pressure (PaO2 in mmHg) to fractional inspired oxygen (FiO2) (P/F) in COVID-19 patients at admission. Materials and Methods: Medical records were retrospectively collected from all adult patients admitted because of COVID-19 from 29 January to 31 July 2020. The association of steroid therapy with 28-day all-cause mortality outcome was analysed in a multivariable logistic regression model adjusted for confounding factors. Results: Overall, 511 patients were analysed, of which 39.1% underwent steroid therapy. Steroid treated patients were mostly male, older, and more frequently treated with antiviral drugs and aminoquinolines; the most common comorbidities were hypertension, followed by cardiovascular disease. Overall, 51 patients died within 28-days, and overall 28-days mortality was 19.5% in the cohort of patients exposed to steroids versus 3.9% mortality in unexposed patients (p < 0.001). Steroid therapy on patients with P/F ratio of 235 mmHg or higher at admission can be considered as detrimental, with an 8% increased probability of death. Conclusions: Steroid therapy is associated with increased 28-day mortality in COVID-19 in patients with mild or no ARDS.
ISSN:2077-0383
2077-0383
DOI:10.3390/jcm10153236